151 related articles for article (PubMed ID: 38037320)
21. Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature.
Ouzzane A; Ghoneim TP; Udo K; Verhasselt-Crinquette M; Puech P; Betrouni N; Rouprêt M; Villers A; Leroy X; Colin P
Cancer Treat Rev; 2011 Aug; 37(5):366-72. PubMed ID: 21257269
[TBL] [Abstract][Full Text] [Related]
22. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.
Kim E; Biswas T; Bakaki P; Dowlati A; Sharma N; Machtay M
Pract Radiat Oncol; 2016; 6(5):e163-e169. PubMed ID: 27142494
[TBL] [Abstract][Full Text] [Related]
23. Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB).
Balasubramanyam S; O'Donnell BP; Musher BL; Jhaveri PM; Ludwig MS
J Gastrointest Cancer; 2019 Jun; 50(2):244-253. PubMed ID: 29354876
[TBL] [Abstract][Full Text] [Related]
24. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network.
Mukesh M; Cook N; Hollingdale AE; Ainsworth NL; Russell SG
BJU Int; 2009 Mar; 103(6):747-52. PubMed ID: 19076139
[TBL] [Abstract][Full Text] [Related]
25. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
26. Survival analysis of small cell carcinomas of the genitourinary system.
Baralo B; Schneider M; Baralo I
Proc (Bayl Univ Med Cent); 2023; 36(1):8-14. PubMed ID: 36578621
[TBL] [Abstract][Full Text] [Related]
27. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the outcomes of pulmonary versus extrapulmonary extensive-stage small cell carcinoma.
Chen E; Yip PY; Tognela A; Gandy G; Earl C; Tran P; Kok PS
Intern Med J; 2024 Mar; 54(3):414-420. PubMed ID: 38009656
[TBL] [Abstract][Full Text] [Related]
30. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
Wee CE; Costello BA; Orme JJ; Quevedo JF; Pagliaro LC
Prostate; 2021 Sep; 81(13):938-943. PubMed ID: 34254332
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
33. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
35. Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
Kubo S; Kobayashi N; Matsumoto H; Somekawa K; Kaneko A; Hashimoto H; Teranishi S; Watanabe K; Horita N; Hara Y; Kudo M; Kaneko T
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17419-17426. PubMed ID: 37878090
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Ueki H; Terakawa T; Hara T; Hirata J; Jimbo N; Okamura Y; Bando Y; Furukawa J; Harada K; Nakano Y; Fujisawa M
Jpn J Clin Oncol; 2023 Jun; 53(6):522-529. PubMed ID: 36828781
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.
Tendler S; Zhan Y; Pettersson A; Lewensohn R; Viktorsson K; Fang F; De Petris L
Acta Oncol; 2020 Apr; 59(4):388-394. PubMed ID: 31910696
[No Abstract] [Full Text] [Related]
38. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
[TBL] [Abstract][Full Text] [Related]
39. Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.
Liao RS; Ruan HT; Jang A; Huynh M; Nadal Rios R; Hoffman-Censits JH; Wei S; Mian OY; Barata PC
Am Soc Clin Oncol Educ Book; 2024 Jan; 44():e430336. PubMed ID: 38176691
[TBL] [Abstract][Full Text] [Related]
40. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.
Pasquier D; Barney B; Sundar S; Poortmans P; Villa S; Nasrallah H; Boujelbene N; Ghadjar P; Lassen-Ramshad Y; Senkus E; Oar A; Roelandts M; Amichetti M; Vees H; Zilli T; Ozsahin M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):904-10. PubMed ID: 26104942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
